

Malcolm D Mason

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7901547/publications.pdf>

Version: 2024-02-01

90
papers

15,932
citations

109137

35
h-index

51492

86
g-index

98
all docs

98
docs citations

98
times ranked

14113
citing authors

#	ARTICLE	IF	CITATIONS
1	Patient- and Tumour-related Prognostic Factors for Urinary Incontinence After Radical Prostatectomy for Nonmetastatic Prostate Cancer: A Systematic Review and Meta-analysis. <i>European Urology Focus</i> , 2022, 8, 674-689.	1.6	21
2	Modern Imaging in Prostate Cancer: Do We Treat Patients, or Their Scans?. <i>European Urology</i> , 2022, 81, 319-322.	0.9	4
3	Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. <i>Lancet, The</i> , 2022, 399, 447-460.	6.3	173
4	Updating and Integrating Core Outcome Sets for Localised, Locally Advanced, Metastatic, and Nonmetastatic Castration-resistant Prostate Cancer: An Update from the PIONEER Consortium. <i>European Urology</i> , 2022, 81, 503-514.	0.9	13
5	Functional and quality of life outcomes of localised prostate cancer treatments (Prostate Testing) Tj ETQq1 1 0.784314 rgBT JOverlo	1.3	23
6	Systematic Review of Active Surveillance for Clinically Localised Prostate Cancer to Develop Recommendations Regarding Inclusion of Intermediate-risk Disease, Biopsy Characteristics at Inclusion and Monitoring, and Surveillance Repeat Biopsy Strategy. <i>European Urology</i> , 2022, 81, 337-346.	0.9	33
7	Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). <i>International Journal of Cancer</i> , 2022, 151, 422-434.	2.3	29
8	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer 2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2021, 79, 243-262.	0.9	1,545
9	Strategies for living well with hormone-responsive advanced prostate cancer: a qualitative exploration. <i>Supportive Care in Cancer</i> , 2021, 29, 1317-1325.	1.0	2
10	EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II 2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer. <i>European Urology</i> , 2021, 79, 263-282.	0.9	633
11	A Systematic Review of the Impact of Surgeon and Hospital Caseload Volume on Oncological and Nononcological Outcomes After Radical Prostatectomy for Nonmetastatic Prostate Cancer. <i>European Urology</i> , 2021, 80, 531-545.	0.9	21
12	Embedding supervised exercise training for men on androgen deprivation therapy into standard prostate cancer care: a feasibility and acceptability study (the STAMINA trial). <i>Scientific Reports</i> , 2021, 11, 12470.	1.6	3
13	A Systematic Review of Focal Ablative Therapy for Clinically Localised Prostate Cancer in Comparison with Standard Management Options: Limitations of the Available Evidence and Recommendations for Clinical Practice and Further Research. <i>European Urology Oncology</i> , 2021, 4, 405-423.	2.6	26
14	Biochemical Recurrence in Prostate Cancer: The European Association of Urology Prostate Cancer Guidelines Panel Recommendations. <i>European Urology Focus</i> , 2020, 6, 231-234.	1.6	131
15	Imaging and T Category for Prostate Cancer in the 8th Edition of the Union for International Cancer Control TNM Classification. <i>European Urology Oncology</i> , 2020, 3, 563-564.	2.6	7
16	The ProtecT trial: analysis of the patient cohort, baseline risk stratification and disease progression. <i>BJU International</i> , 2020, 125, 506-514.	1.3	32
17	Ten-year Mortality, Disease Progression, and Treatment-related Side Effects in Men with Localised Prostate Cancer from the ProtecT Randomised Controlled Trial According to Treatment Received. <i>European Urology</i> , 2020, 77, 320-330.	0.9	107
18	The ProtecT randomised trial cost-effectiveness analysis comparing active monitoring, surgery, or radiotherapy for prostate cancer. <i>British Journal of Cancer</i> , 2020, 123, 1063-1070.	2.9	15

#	ARTICLE	IF	CITATIONS
19	Benefits and Risks of Primary Treatments for High-risk Localized and Locally Advanced Prostate Cancer: An International Multidisciplinary Systematic Review. <i>European Urology</i> , 2020, 77, 614-627.	0.9	101
20	Active monitoring, radical prostatectomy and radical radiotherapy in PSA-detected clinically localised prostate cancer: the ProtecT three-arm RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-176.	1.3	22
21	Global Consultation on Cancer Staging: promoting consistent understanding and use. <i>Nature Reviews Clinical Oncology</i> , 2019, 16, 763-771.	12.5	52
22	Cancer-related symptoms, mental well-being, and psychological distress in men diagnosed with prostate cancer treated with androgen deprivation therapy. <i>Quality of Life Research</i> , 2019, 28, 2741-2751.	1.5	21
23	Quality of life among symptomatic compared to PSA-detected prostate cancer survivors - results from a UK wide patient-reported outcomes study. <i>BMC Cancer</i> , 2019, 19, 947.	1.1	4
24	EAU-EANM-ESTRO-ESUR-SIOG Prostate Cancer Guideline Panel Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer from an International Collaborative Study (DETECTIVE Study). <i>European Urology</i> , 2019, 76, 790-813.	0.9	151
25	Patients' and partners' views of care and treatment provided for metastatic castrate-resistant prostate cancer in the UK. <i>European Journal of Cancer Care</i> , 2019, 28, e13140.	0.7	7
26	Abiraterone in High- and Low-risk Metastatic Hormone-sensitive Prostate Cancer. <i>European Urology</i> , 2019, 76, 719-728.	0.9	142
27	Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study. <i>Lancet Oncology</i> , The, 2019, 20, 436-447.	5.1	100
28	Regional Variations in Quality of Survival Among Men with Prostate Cancer Across the United Kingdom. <i>European Urology</i> , 2019, 76, 228-237.	0.9	6
29	Study Protocol for the DETECTIVE Study: An International Collaborative Study To Develop Consensus Statements for Deferred Treatment with Curative Intent for Localised Prostate Cancer. <i>European Urology</i> , 2019, 75, 699-702.	0.9	8
30	Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2019, 75, 967-987.	0.9	278
31	Reply to Massimo Valerio, Mark Emberton, and Hashim U. Ahmed's Letter to the Editor re: Henk G. van der Poel, Roderick C.N. van den Bergh, Erik Briers, et al. Focal Therapy in Primary Localised Prostate Cancer: The European Association of Urology Position in 2018. <i>Eur Urol</i> 2018;74:84-91. <i>European Urology</i> , 2019, 75, e23-e24.	0.9	0
32	Importance of activated leukocyte cell adhesion molecule (ALCAM) in prostate cancer progression and metastatic dissemination. <i>Oncotarget</i> , 2019, 10, 6362-6377.	0.8	12
33	Urinary, bowel and sexual health in older men from Northern Ireland. <i>BJU International</i> , 2018, 122, 845-857.	1.3	18
34	Adoption of robotic surgery: driven by market competition or a desire to improve patient care? Authors' reply. <i>Lancet Oncology</i> , The, 2018, 19, e67.	5.1	0
35	Focal Therapy in Primary Localised Prostate Cancer : The European Association of Urology Position in 2018. <i>European Urology</i> , 2018, 74, 84-91.	0.9	136
36	A prospective cohort and extended comprehensive-cohort design provided insights about the generalizability of a pragmatic trial: the ProtecT prostate cancer trial. <i>Journal of Clinical Epidemiology</i> , 2018, 96, 35-46.	2.4	16

#	ARTICLE	IF	CITATIONS
37	Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition. <i>European Urology</i> , 2018, 73, 822-825.	0.9	33
38	Addition of Docetaxel to First-line Long-term Hormone Therapy in Prostate Cancer (STAMPEDE): Modelling to Estimate Long-term Survival, Quality-adjusted Survival, and Cost-effectiveness. <i>European Urology Oncology</i> , 2018, 1, 449-458.	2.6	19
39	Systematic review update of observational studies further supports aspirin role in cancer treatment: Time to share evidence and decision-making with patients?. <i>PLoS ONE</i> , 2018, 13, e0203957.	1.1	31
40	Somatic cancer genetics in the UK: real-world data from phase I of the Cancer Research UK Stratified Medicine Programme. <i>ESMO Open</i> , 2018, 3, e000408.	2.0	4
41	Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. <i>Lancet, The</i> , 2018, 392, 2353-2366.	6.3	901
42	Re: Enzalutamide in Men with Nonmetastatic, Castration-resistant Prostate Cancer. <i>European Urology</i> , 2018, 74, 845.	0.9	0
43	Soluble interleukin-6 receptor mediated fatigue highlights immunological heterogeneity of patients with early breast cancer who undergo radiation therapy. <i>Advances in Radiation Oncology</i> , 2018, 3, 552-558.	0.6	4
44	Degarelix Versus Goserelin Plus Bicalutamide in the Short-term Relief of Lower Urinary Tract Symptoms in Prostate Cancer Patients: Results of a Pooled Analysis. <i>LUTS: Lower Urinary Tract Symptoms</i> , 2017, 9, 82-88.	0.6	6
45	The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2017, 72, 84-109.	0.9	348
46	Molecular Subgroup of Primary Prostate Cancer Presenting with Metastatic Biology. <i>European Urology</i> , 2017, 72, 509-518.	0.9	26
47	Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy. <i>New England Journal of Medicine</i> , 2017, 377, 338-351.	13.9	1,315
48	Dual roles of protein tyrosine phosphatase kappa in coordinating angiogenesis induced by pro-angiogenic factors. <i>International Journal of Oncology</i> , 2017, 50, 1127-1135.	1.4	2
49	Effect of patient choice and hospital competition on service configuration and technology adoption within cancer surgery: a national, population-based study. <i>Lancet Oncology, The</i> , 2017, 18, 1445-1453.	5.1	74
50	Hospital Quality Factors Influencing the Mobility of Patients for Radical Prostate Cancer Radiation Therapy: A National Population-Based Study. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, 1261-1270.	0.4	28
51	Quality of Life Outcomes after Primary Treatment for Clinically Localised Prostate Cancer: A Systematic Review. <i>European Urology</i> , 2017, 72, 869-885.	0.9	182
52	Adding abiraterone to androgen deprivation therapy in men with metastatic hormone-sensitive prostate cancer: A systematic review and meta-analysis. <i>European Journal of Cancer</i> , 2017, 84, 88-101.	1.3	128
53	EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. <i>European Urology</i> , 2017, 71, 618-629.	0.9	2,497
54	Mortality Among Men with Advanced Prostate Cancer Excluded from the ProtecT Trial. <i>European Urology</i> , 2017, 71, 381-388.	0.9	41

#	ARTICLE	IF	CITATIONS
55	Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial. <i>Journal of Clinical Oncology</i> , 2017, 35, 1530-1541.	0.8	54
56	Potential Implication of Paxillin in Cancer Establishment Within the Bone Environment. <i>Anticancer Research</i> , 2017, 37, 4255-4268.	0.5	4
57	STAMPEDE trial and patients with non-metastatic prostate cancer – Authors' reply. <i>Lancet, The</i> , 2016, 388, 235-236.	6.3	6
58	Radiotherapy for Prostate Cancer: is it “what you do” or “the way that you do it”? A UK Perspective on Technique and Quality Assurance. <i>Clinical Oncology</i> , 2016, 28, e92-e100.	0.6	7
59	10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1415-1424.	13.9	2,101
60	Patient-Reported Outcomes after Monitoring, Surgery, or Radiotherapy for Prostate Cancer. <i>New England Journal of Medicine</i> , 2016, 375, 1425-1437.	13.9	962
61	Patient-reported outcomes in the ProtecT randomized trial of clinically localized prostate cancer treatments: study design, and baseline urinary, bowel and sexual function and quality of life. <i>BJU International</i> , 2016, 118, 869-879.	1.3	52
62	Estimating the Impact of Randomised Control Trial Results on Clinical Practice: Results from a Survey and Modelling Study of Androgen Deprivation Therapy plus Radiotherapy for Locally Advanced Prostate Cancer. <i>European Urology Focus</i> , 2016, 2, 276-283.	1.6	2
63	Importance of osteoprotegerin and receptor activator of nuclear factor κ B in breast cancer response to hepatocyte growth factor and the bone microenvironment in vitro. <i>International Journal of Oncology</i> , 2016, 48, 919-928.	1.4	4
64	Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial. <i>Lancet, The</i> , 2016, 387, 1163-1177.	6.3	1,570
65	Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data. <i>Lancet Oncology, The</i> , 2016, 17, 243-256.	5.1	361
66	Prostate stromal cell proteomics analysis discriminates normal from tumour reactive stromal phenotypes. <i>Oncotarget</i> , 2016, 7, 20124-20139.	0.8	27
67	Prostate Apoptosis Response-4 (PAR4) Suppresses Growth and Invasion of Breast Cancer Cells and Is Positively Associated with Patient Survival. <i>Anticancer Research</i> , 2016, 36, 1227-35.	0.5	4
68	YangZheng Xiaoji exerts anti-tumour growth effects by antagonising the effects of HGF and its receptor, cMET, in human lung cancer cells. <i>Journal of Translational Medicine</i> , 2015, 13, 280.	1.8	10
69	Traditional Chinese medicine in the prevention and treatment of cancer and cancer metastasis. <i>Oncology Letters</i> , 2015, 10, 1240-1250.	0.8	115
70	Prostate Cancer Unit Initiative in Europe: A position paper by the European School of Oncology. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 95, 133-143.	2.0	23
71	Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. <i>Journal of Clinical Oncology</i> , 2015, 33, 2143-2150.	0.8	213
72	Cross-Presentation of the Oncofetal Tumor Antigen 5T4 from Irradiated Prostate Cancer Cells – A Key Role for Heat-Shock Protein 70 and Receptor CD91. <i>Cancer Immunology Research</i> , 2015, 3, 678-688.	1.6	37

#	ARTICLE	IF	CITATIONS
73	EPLIN: a fundamental actin regulator in cancer metastasis?. <i>Cancer and Metastasis Reviews</i> , 2015, 34, 753-764.	2.7	37
74	Cancer exosomes trigger mesenchymal stem cell differentiation into pro-angiogenic and pro-invasive myofibroblasts. <i>Oncotarget</i> , 2015, 6, 715-731.	0.8	227
75	Expression of Sonic Hedgehog (SHH) in human lung cancer and the impact of YangZheng Xiaoji on SHH-mediated biological function of lung cancer cells and tumor growth. <i>Anticancer Research</i> , 2015, 35, 1321-31.	0.5	14
76	Therapeutic potential of capillary morphogenesis gene 2 extracellular vWA domain in tumour-related angiogenesis. <i>International Journal of Oncology</i> , 2014, 45, 1565-1573.	1.4	8
77	Capillary morphogenesis gene 2 regulates adhesion and invasiveness of prostate cancer cells. <i>Oncology Letters</i> , 2014, 7, 2149-2153.	0.8	8
78	Active monitoring, radical prostatectomy, or radiotherapy for localised prostate cancer: study design and diagnostic and baseline results of the ProtecT randomised phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 1109-1118.	5.1	205
79	Tumor stroma-derived factors skew monocyte to dendritic cell differentiation toward a suppressive CD14 ⁺ PD-L1 ⁺ phenotype in prostate cancer. <i>Oncolmmunology</i> , 2014, 3, e955331.	2.1	59
80	Combining Enzalutamide with Abiraterone, Prednisone, and Androgen Deprivation Therapy in the STAMPEDE Trial. <i>European Urology</i> , 2014, 66, 799-802.	0.9	56
81	Tumour angiogenesis and repulsive guidance molecule b: A role in HGF- and BMP-7-mediated angiogenesis. <i>International Journal of Oncology</i> , 2014, 45, 1304-1312.	1.4	15
82	HGF and the regulation of tight junctions in human prostate cancer cells. <i>Oncology Reports</i> , 2014, 32, 213-224.	1.2	13
83	Psychological and immunological characteristics of fatigued women undergoing radiotherapy for early-stage breast cancer. <i>Supportive Care in Cancer</i> , 2013, 21, 173-181.	1.0	36
84	Re: Predictors of Androgen Deprivation Therapy Efficacy Combined with Prostatic Irradiation: The Central Role of Tumor Stage and Radiation Dose. <i>European Urology</i> , 2011, 60, 179-180.	0.9	1
85	Degarelix: a new hormonal treatment for prostate cancer. <i>Future Prescriber</i> , 2009, 10, 11-15.	0.1	2
86	Management of prostate cancer: future treatment approaches. <i>Future Prescriber</i> , 2009, 10, 9-12.	0.1	1
87	Oral Sodium Clodronate for Nonmetastatic Prostate Cancer--Results of a Randomized Double-Blind Placebo-Controlled Trial: Medical Research Council PR04 (ISRCTN61384873). <i>Journal of the National Cancer Institute</i> , 2007, 99, 765-776.	3.0	103
88	What implications do the tolerability profiles of antiandrogens and other commonly used prostate cancer treatments have on patient care?. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 27-35.	1.2	12
89	The Vitality Index: Vital decisions in locally advanced prostate cancer. <i>NursePrescribing</i> , 2005, 3, S3-S7.	0.1	0
90	Cell adhesion molecules and adhesion abnormalities in prostate cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2002, 41, 11-28.	2.0	52